Talking about climate change may be politically radioactive, but adjusting to its effects is no longer optional.

Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells (Treg) -preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study ...